Otsuka Corporation (TYO:4768)
2,865.50
-14.00 (-0.49%)
May 2, 2025, 3:30 PM JST
Otsuka Revenue
Otsuka had revenue of 315.54B JPY in the quarter ending March 31, 2025, with 18.33% growth. This brings the company's revenue in the last twelve months to 1.16T, up 15.49% year-over-year. In the year 2024, Otsuka had annual revenue of 1.11T with 13.33% growth.
Revenue (ttm)
1,156.55B
Revenue Growth
+15.49%
P/S Ratio
0.94
Revenue / Employee
119.48M
Employees
9,680
Market Cap
1,086.60B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,107.67B | 130.30B | 13.33% |
Dec 31, 2023 | 977.37B | 116.35B | 13.51% |
Dec 31, 2022 | 861.02B | 9.13B | 1.07% |
Dec 31, 2021 | 851.89B | 15.57B | 1.86% |
Dec 31, 2020 | 836.32B | -50.21B | -5.66% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sony Group | 13.81T |
Keyence | 1,059.15B |
Nintendo | 1,233.29B |
Tokyo Electron | 2,323.46B |
Fujitsu | 3,550.12B |
NEC Corporation | 3,423.43B |
Advantest | 779.71B |
Murata Manufacturing | 1,721.90B |
Otsuka News
- 5 weeks ago - Arbitrum DAO mulls winding down unsustainable Web3 gaming fund - Cointelegraph
- 2 months ago - Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much? - Seeking Alpha
- 2 months ago - Vera plunges as Otsuka updates on rival therapy - Seeking Alpha
- 5 months ago - Otsuka submits NDA in Japan for the treatment of hypercholesterolemia - Seeking Alpha
- 6 months ago - ICU Medical, Otsuka team up to boost US IV solutions production - Seeking Alpha
- 7 months ago - Otsuka Is Said to Weigh Sale of Stake in Medical Device Maker MicroPort Scientific - BNN Bloomberg
- 8 months ago - Citi maintains ‘Sell’ rating on Lupin, sets target at Rs 1,700 - Business Upturn